Identification of Targets of a New Nutritional Mixture for Osteoarthritis Management Composed by Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract.
OBJECTIVE
We have previously demonstrated that a mixture of curcuminoids extract, hydrolyzed collagen and green tea extract (COT) inhibited inflammatory and catabolic mediator's synthesis by osteoarthritic human chondrocytes. The objective of this study was to identify new targets of COT using genomic and proteomic approaches.


METHODS
Cartilage specimens were obtained from 12 patients with knee osteoarthritis. Primary human chondrocytes were cultured in monolayer until confluence and then incubated for 24 or 48 hours in the absence or in the presence of human interleukin(IL)-1β (10-11M) and with or without COT, each compound at the concentration of 4 μg/ml. Microarray gene expression profiling between control, COT, IL-1β and COT IL-1β conditions was performed. Immunoassays were used to confirm the effect of COT at the protein level.


RESULTS
More than 4000 genes were differentially expressed between conditions. The key regulated pathways were related to inflammation, cartilage metabolism and angiogenesis. The IL-1β stimulated chemokine ligand 6, matrix metalloproteinase-13, bone morphogenetic protein-2 and stanniocalcin1 gene expressions and protein productions were down-regulated by COT. COT significantly decreased stanniocalcin1 production in basal condition. Serpin E1 gene expression and protein production were down-regulated by IL-1β. COT reversed the inhibitory effect of IL-1β. Serpin E1 gene expression was up-regulated by COT in control condition.


CONCLUSIONS
The COT mixture has beneficial effect on osteoarthritis physiopathology by regulating the synthesis of key catabolic, inflammatory and angiogenesis factors. These findings give a scientific rationale for the use of these natural ingredients in the management of osteoarthritis.
Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Liège, Belgium.
Fanny
F
Comblain
Orthopedic Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Jean-Emile
JE
Dubuc
Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Liège, Belgium.
Cécile
C
Lambert
Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Liège, Belgium.
Christelle
C
Sanchez
Royal Canin Research Center, Aimargues, France.
Isabelle
I
Lesponne
Royal Canin Research Center, Aimargues, France.
Samuel
S
Serisier
Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Liège, Belgium.|Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium.
Yves
Y
Henrotin
D000368:Aged; D002478:Cells, Cultured; D019902:Chondrocytes / Q000378:metabolism* / Q000473:pathology; D003094:Collagen / Q000737:chemistry*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006023:Glycoproteins / Q000096:biosynthesis; D006801:Humans; D053583:Interleukin-1beta / Q000096:biosynthesis; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000096:biosynthesis; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis; D011492:Protein Hydrolysates / Q000737:chemistry / Q000494:pharmacology*; D013662:Tea / Q000737:chemistry*
D006023:Glycoproteins; C508585:IL1B protein, human; D053583:Interleukin-1beta; D010936:Plant Extracts; D017395:Plasminogen Activator Inhibitor 1; D011492:Protein Hydrolysates; D013662:Tea; C051795:teleocalcin; D003094:Collagen; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2